Eisai's lecanemab, like Aduhelm, is a monoclonal antibody designed to remove beta-amyloid, a type of protein fragment that accumulates in brains

Japan’s Eisai saw its US listed shares rise 56% – up by more than Biogen’s 38% jump after US regulators...